U.S. Food and Drug Administration Approves ABRAXANE(R) in Combination with Gemcitabine as First-Line Treatment of Patients with Metastatic Pancreatic Cancer
Approval Based on MPACT Study of ABRAXANE in Combination with Gemcitabine Demonstrating a Clinically Meaningful Increase in Overall Survival
First New Treatment Approved for Metastatic Adenocarcinoma of the Pancreas in Nearly 8 Years
SUMMIT, N.J.--(H... Biopharmaceuticals, Oncology, FDACelgene, ABRAXANE, paclitaxel, Pancreatic Cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Abraxane | Adenocarcinoma | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Pancreas | Pancreatic Cancer | Pharmaceuticals | Study